MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech company, announced the pricing of an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and 1 million pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The company plans to use the net proceeds to fund research, development, and commercialization activities for sonelokimab, its investigational treatment for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. The offering is expected to close on or about June 25, 2026.